HIA
ADMA icon

HFM Investment Advisors’s ADMA Biologics ADMA Stock Holding History

HFM Investment Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$63 Sell
7
-2
-22% -$32 ﹤0.01% 1157
2025
Q4 		$165 Buy
9
+4
+80% +$67 ﹤0.01% 1074
2025
Q3 		$73 Sell
5
-11
-69% -$189 ﹤0.01% 1193
2025
Q2 		$291 Buy
16
+13
+433% +$265 ﹤0.01% 857
2025
Q1 		$60 Buy
+3
New +$52 ﹤0.01% 1001

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

HFM Investment Advisors's ADMA Position: Q1 2026 in Review

HFM Investment Advisors reduced its ADMA Biologics (ADMA) stake by 22% in Q1 2026, selling an estimated $32 and leaving 7 shares worth $63. The position accounts for ﹤0.01% of the portfolio, ranked #1157.

HFM Investment Advisors first reported a position in ADMA in Q1 2025 and has held it in 5 quarters since. The position peaked at $291 in Q2 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • HFM Investment Advisors held 7 shares of ADMA Biologics worth $63 as of Q1 2026.
  • HFM Investment Advisors sold 2 ADMA Biologics shares in Q1 2026, an estimated $32.
  • ADMA Biologics made up ﹤0.01% of HFM Investment Advisors's portfolio in Q1 2026, its #1157 holding.
  • HFM Investment Advisors first reported a position in ADMA Biologics in Q1 2025 and has held it in 5 quarters since.
  • HFM Investment Advisors's ADMA Biologics position peaked at $291 in Q2 2025.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on HFM Investment Advisors's 13F filing for Q1 2026, filed 1 May 2026.